Correlation Between Monopar Therapeutics and Lipella Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Monopar Therapeutics and Lipella Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monopar Therapeutics and Lipella Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Monopar Therapeutics and Lipella Pharmaceuticals Common, you can compare the effects of market volatilities on Monopar Therapeutics and Lipella Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monopar Therapeutics with a short position of Lipella Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monopar Therapeutics and Lipella Pharmaceuticals.

Diversification Opportunities for Monopar Therapeutics and Lipella Pharmaceuticals

0.31

Correlation Coefficient

Monopar Therapeutics  Lipella Pharmaceuticals

Weak diversification

The 3 months correlation between Monopar and Lipella is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Monopar Therapeutics and Lipella Pharmaceuticals Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipella Pharmaceuticals and Monopar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monopar Therapeutics are associated (or correlated) with Lipella Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipella Pharmaceuticals has no effect on the direction of Monopar Therapeutics i.e., Monopar Therapeutics and Lipella Pharmaceuticals go up and down completely randomly.

Pair Corralation between Monopar Therapeutics and Lipella Pharmaceuticals

Given the investment horizon of 90 days Monopar Therapeutics is expected to generate 0.61 times more return on investment than Lipella Pharmaceuticals. However, Monopar Therapeutics is 1.63 times less risky than Lipella Pharmaceuticals. It trades about 0.14 of its potential returns per unit of risk. Lipella Pharmaceuticals Common is currently generating about 0.03 per unit of risk. If you would invest  2,385  in Monopar Therapeutics on December 29, 2024 and sell it today you would earn a total of  1,648  from holding Monopar Therapeutics or generate 69.1% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Monopar Therapeutics  vs.  Lipella Pharmaceuticals Common

Monopar Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Monopar Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Monopar Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Lipella Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lipella Pharmaceuticals Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Lipella Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Monopar Therapeutics and Lipella Pharmaceuticals

The main advantage of trading using opposite Monopar Therapeutics and Lipella Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monopar Therapeutics position performs unexpectedly, Lipella Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will offset losses from the drop in Lipella Pharmaceuticals' long position.

The idea behind Monopar Therapeutics and Lipella Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.